Brown, Lisle/Cummings, Inc. Vertex Pharmaceuticals Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $335 Billion
- Q4 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 75 shares of VRTX stock, worth $34,626. This represents 0.01% of its overall portfolio holdings.
Number of Shares
75Holding current value
$34,626% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,705Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.4 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.7 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.84 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.46 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.16 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $119B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...